Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

784 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Protocol of an open, three-arm, individually randomized trial assessing the effect of delivering sexual and reproductive health information to young people (aged 13-24) in Kenya and Peru via mobile phones: adolescent/youth reproductive mobile access and delivery initiative for love and life outcomes (ARMADILLO) study stage 2.
Gonsalves L, Hindin MJ, Bayer A, Carcamo CP, Gichangi P, Habib N, Mwaisaka J, Say L. Gonsalves L, et al. Among authors: habib n. Reprod Health. 2018 Jul 11;15(1):126. doi: 10.1186/s12978-018-0568-6. Reprod Health. 2018. PMID: 29996854 Free PMC article. Clinical Trial.
Two prophylactic medication approaches in addition to a pain control regimen for early medical abortion < 63 days' gestation with mifepristone and misoprostol: study protocol for a randomized, controlled trial.
Dragoman MV, Grossman D, Kapp N, Huong NM, Habib N, Dung DL, Tamang A. Dragoman MV, et al. Among authors: habib n. Reprod Health. 2016 Oct 12;13(1):132. doi: 10.1186/s12978-016-0246-5. Reprod Health. 2016. PMID: 27733165 Free PMC article. Clinical Trial.
The ARMADILLO text message intervention to improve the sexual and reproductive health knowledge of adolescents in Peru: Results of a randomized controlled trial.
Perez-Lu JE, Guerrero F, Cárcamo CP, Alburqueque M, Chiappe M, Hindin MJ, Habib N, Say L, Gonsalves L, Bayer AM. Perez-Lu JE, et al. Among authors: habib n. PLoS One. 2022 Feb 10;17(2):e0262986. doi: 10.1371/journal.pone.0262986. eCollection 2022. PLoS One. 2022. PMID: 35143513 Free PMC article. Clinical Trial.
A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls.
Bahamondes L, Brache V, Meirik O, Ali M, Habib N, Landoulsi S; WHO Study Group on Contraceptive Implants for Women. Bahamondes L, et al. Among authors: habib n. Hum Reprod. 2015 Nov;30(11):2527-38. doi: 10.1093/humrep/dev221. Epub 2015 Sep 25. Hum Reprod. 2015. PMID: 26409014 Clinical Trial.
A prospective, open-label, single arm, multicentre study to evaluate efficacy, safety and acceptability of pericoital oral contraception using levonorgestrel 1.5 mg.
Festin MP, Bahamondes L, Nguyen TM, Habib N, Thamkhantho M, Singh K, Gosavi A, Bartfai G, Bito T, Bahamondes MV, Kapp N. Festin MP, et al. Among authors: habib n. Hum Reprod. 2016 Mar;31(3):530-40. doi: 10.1093/humrep/dev341. Epub 2016 Jan 31. Hum Reprod. 2016. PMID: 26830816 Free PMC article. Clinical Trial.
Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant.
Ali M, Akin A, Bahamondes L, Brache V, Habib N, Landoulsi S, Hubacher D; WHO study group on subdermal contraceptive implants for women. Ali M, et al. Among authors: habib n. Hum Reprod. 2016 Nov;31(11):2491-2498. doi: 10.1093/humrep/dew222. Epub 2016 Sep 26. Hum Reprod. 2016. PMID: 27671673 Free PMC article. Clinical Trial.
784 results